# Study of NTB-928 in R/R OC

> **NCT07690189** · PHASE1 · RECRUITING · sponsor: **TeneoSeven, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Relapsed/Refractory Ovarian Carcinoma

## Interventions

- **DRUG:** NTB-928

## Key facts

- **NCT ID:** NCT07690189
- **Lead sponsor:** TeneoSeven, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2028-06
- **Final completion:** 2029-02
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690189, "Study of NTB-928 in R/R OC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*